A 28 week, randomized, double-blind, placebo-controlled, two-part, multicenter, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal muscle strength and function in older adults with sarcopenia (InvestiGAIT)

Trial Profile

A 28 week, randomized, double-blind, placebo-controlled, two-part, multicenter, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal muscle strength and function in older adults with sarcopenia (InvestiGAIT)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 May 2018

At a glance

  • Drugs Bimagrumab (Primary)
  • Indications Muscular atrophy
  • Focus Therapeutic Use
  • Acronyms InvestiGAIT
  • Sponsors Novartis
  • Most Recent Events

    • 29 May 2018 The study has been completed in Denmark.
    • 10 Nov 2017 Planned number of patients changed from 280 to 339.
    • 12 Apr 2017 Planned End Date changed from 16 Dec 2018 to 13 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top